Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes : the HOVON89 trial
© 2024. The Author(s)..
A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Leukemia - 38(2024), 4 vom: 19. Apr., Seite 840-850 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van de Loosdrecht, A A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
143011-72-7 |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 24.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-024-02161-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367864436 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367864436 | ||
| 003 | DE-627 | ||
| 005 | 20240425232805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240201s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-024-02161-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM367864436 | ||
| 035 | |a (NLM)38297135 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van de Loosdrecht, A A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes |b the HOVON89 trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10) | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 650 | 7 | |a Hematinics |2 NLM | |
| 650 | 7 | |a Granulocyte Colony-Stimulating Factor |2 NLM | |
| 650 | 7 | |a 143011-72-7 |2 NLM | |
| 700 | 1 | |a Cremers, E M P |e verfasserin |4 aut | |
| 700 | 1 | |a Alhan, C |e verfasserin |4 aut | |
| 700 | 1 | |a Duetz, C |e verfasserin |4 aut | |
| 700 | 1 | |a In 't Hout, F E M |e verfasserin |4 aut | |
| 700 | 1 | |a Visser-Wisselaar, H A |e verfasserin |4 aut | |
| 700 | 1 | |a Chitu, D A |e verfasserin |4 aut | |
| 700 | 1 | |a Verbrugge, A |e verfasserin |4 aut | |
| 700 | 1 | |a Cunha, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Ossenkoppele, G J |e verfasserin |4 aut | |
| 700 | 1 | |a Janssen, J J W M |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, S K |e verfasserin |4 aut | |
| 700 | 1 | |a Vellenga, E |e verfasserin |4 aut | |
| 700 | 1 | |a Huls, G A |e verfasserin |4 aut | |
| 700 | 1 | |a Muus, P |e verfasserin |4 aut | |
| 700 | 1 | |a Langemeijer, S M C |e verfasserin |4 aut | |
| 700 | 1 | |a de Greef, G E |e verfasserin |4 aut | |
| 700 | 1 | |a Te Boekhorst, P A W |e verfasserin |4 aut | |
| 700 | 1 | |a Raaijmakers, M H G |e verfasserin |4 aut | |
| 700 | 1 | |a van Marwijk Kooy, M |e verfasserin |4 aut | |
| 700 | 1 | |a Legdeur, M C |e verfasserin |4 aut | |
| 700 | 1 | |a Wegman, J J |e verfasserin |4 aut | |
| 700 | 1 | |a Deenik, W |e verfasserin |4 aut | |
| 700 | 1 | |a de Weerdt, O |e verfasserin |4 aut | |
| 700 | 1 | |a van Maanen-Lamme, T M |e verfasserin |4 aut | |
| 700 | 1 | |a Jobse, P |e verfasserin |4 aut | |
| 700 | 1 | |a van Kampen, R J W |e verfasserin |4 aut | |
| 700 | 1 | |a Beeker, A |e verfasserin |4 aut | |
| 700 | 1 | |a Wijermans, P W |e verfasserin |4 aut | |
| 700 | 1 | |a Biemond, B J |e verfasserin |4 aut | |
| 700 | 1 | |a Tanis, B C |e verfasserin |4 aut | |
| 700 | 1 | |a van Esser, J W J |e verfasserin |4 aut | |
| 700 | 1 | |a Schaar, C G |e verfasserin |4 aut | |
| 700 | 1 | |a Noordzij-Nooteboom, H S |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, E M G |e verfasserin |4 aut | |
| 700 | 1 | |a de Graaf, A O |e verfasserin |4 aut | |
| 700 | 1 | |a Jongen-Lavrencic, M |e verfasserin |4 aut | |
| 700 | 1 | |a Stevens-Kroef, M J P L |e verfasserin |4 aut | |
| 700 | 1 | |a Westers, T M |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen, J H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 38(2024), 4 vom: 19. Apr., Seite 840-850 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:4 |g day:19 |g month:04 |g pages:840-850 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-024-02161-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 4 |b 19 |c 04 |h 840-850 | ||